This new report focuses on a segment of cancer vaccines companies. It delivers advanced market profiling, interactive mindmaps, information about companies and investors, technology application use cases and other actionable information. 
The current report version reviewed the 5 cancer vaccine platforms: Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform — and the latest breakthrough and a potentially disruptive research strategy —  Antigenic Essence Platform, which are actively developing their products to enter the market of immunotherapy. As a result we conducted assessment of more than 245 investors, 150 companies and R&D centers, and detailed analysis of more than 30 of them.